Adult participants with advanced unresectable or metastatic soft-tissue sarcoma. research hub

CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZED PHASE II STUDY

This study is looking at two new drug combinations for adults with advanced soft-tissue sarcoma. It aims to see if a combination of nivolumab and relatlimab, or nivolumab alone, can help control the cancer for at least six months. The trial is in its early stages.